The company has not filed an annual or quarterly report since its FY2024 20-F, filed May 9, 2025. Its latest SEC filing is a 15-12G from Dec 3, 2025.
20-F for FY2024, filed May 9, 2025
The sections below describe the company as of the FY2024 annual report.
Develops donor-derived immune-cell therapies intended to treat patients with cancers and viral infections.
20-F for FY2024, filed May 9, 2025
Partners pay for collaborative research and development. Upfront payments are spread over the service period, and partners reimburse research costs as those costs are incurred; payment terms are typically 30-60 days.
20-F for FY2024, filed May 9, 2025The Company earned revenue from collaboration agreements and contracts with customers. Revenue is recognized on upfront collaboration…View ↗
The terms of business for payment on satisfaction of a performance obligation are typically 30-60 days. Collaboration agreements entered…View ↗
Revenue from reimbursement of research and development costs by collaboration partners is recognized as the costs are incurred.View ↗
GBP 3.8M
20-F for FY2024, filed May 10, 2025
GBP 3.8M ↗
Partners fund or partly fund collaborative research and development, while physicians who participate in the company's clinical studies are described as future customers.
20-F for FY2024, filed May 9, 2025
No. It lost GBP 1.3M in FY2022.
20-F for FY2024, filed May 10, 2025
−GBP 12.1MView ↗
20-F for FY2024, filed May 10, 2025
−GBP 1.3MView ↗
20-F for FY2024, filed May 10, 2025
−GBP 15.5MView ↗
Competes with AdicetBio, Allogene, Autolus, Gamma Delta Therapeutics, In8Bio, Novartis, Gilead, and Bristol Myers Squibb
20-F for FY2024, filed May 9, 2025TC BioPharm is part of a growing number of companies commercially active in the cellular immunotherapy space. Such companies developing…View ↗
Loading...
